Welcome to our dedicated page for Vera Therapeutics news (Ticker: VERA), a resource for investors and traders seeking the latest updates and insights on Vera Therapeutics stock.
Vera Therapeutics develops treatments for serious immunological diseases, with company updates centered on atacicept, a self-administered fusion protein designed to block BAFF and APRIL activity involved in autoantibody production. News commonly covers the atacicept program in IgA nephropathy, related autoimmune kidney disease research, clinical data from the ORIGIN and PIONEER programs, FDA regulatory communications, and preparations tied to potential commercialization.
Other recurring developments include quarterly financial results, balance sheet and financing commentary, participation in health care conferences, board and executive appointments, and equity-based inducement awards under Nasdaq Listing Rule 5635(c)(4).
Vera Therapeutics, a clinical-stage biotechnology company, announced that its CEO, Marshall Fordyce, MD, will present at the 42nd Annual Cowen Health Care Conference from March 7-9, 2022. The presentation is scheduled for March 9 from 2:10-3:10 PM ET in a corporate panel discussion format. A live audio webcast will be available for those interested. Vera Therapeutics focuses on developing treatments for serious immunological diseases, with its lead product candidate, atacicept, targeting autoimmune diseases like IgA nephropathy and lupus nephritis.
Vera Therapeutics has successfully closed a public offering of 5,742,026 shares of Class A common stock at $15.00 per share, raising approximately $86.1 million in gross proceeds. This includes the full exercise of the underwriters’ option for an additional 748,959 shares. The offering was managed by J.P. Morgan, Cowen, and Evercore ISI. Registration statements for the securities became effective on February 9 and 10, 2022, and all shares offered were sold by Vera.
Vera Therapeutics, Inc. (Nasdaq: VERA) announced a public offering of 4,993,067 shares of Class A common stock priced at $15.00 per share, aiming to raise approximately $74.9 million before expenses. All shares are offered by the company, with an additional option for underwriters to purchase 748,959 shares within 30 days. The offering is set to close on February 14, 2022, pending customary conditions. J.P. Morgan, Cowen, and Evercore ISI are acting as the joint book-running managers. The securities registration was approved by the SEC on February 9 and 10, 2022.
On February 7, 2022, Vera Therapeutics announced a public offering of 4,000,000 shares of its Class A common stock, with all shares being offered by the company. The underwriters may purchase an additional 600,000 shares within a 30-day option. The offering is subject to market conditions and customary closing prerequisites. J.P. Morgan, Cowen, and Evercore ISI are managing the offering. The registration statement is filed with the SEC and is accessible online. Vera Therapeutics focuses on treatments for serious immunological diseases with candidates like atacicept and MAU868.
Vera Therapeutics announced plans to initiate a Phase 3 trial for atacicept in treating lupus nephritis (LN) following positive feedback from the FDA. The trial will assess the efficacy and safety of atacicept in patients with LN, addressing a critical need as current treatments have limited effectiveness. The trial features a 52-week treatment period, focusing on complete renal response as the primary endpoint. Vera is also advancing trials for other indications, including immunoglobulin A nephropathy (IgAN) and BK virus infections in kidney transplant patients.
Vera Therapeutics, a clinical-stage biotechnology company, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, from 3:45-4:25 PM ET. CEO Marshall Fordyce will lead the presentation and engage in one-on-one investor meetings during the event, taking place virtually from January 10-13, 2022. A live audio webcast of the presentation will be available online, with a replay accessible for 30 days. The company focuses on innovative treatments for serious immunological diseases, including its lead product candidate, atacicept, targeting autoimmune disorders.
Vera Therapeutics has announced the acquisition of MAU868, a first-in-class monoclonal antibody targeting BK Virus (BKV) infections, which is a significant cause of kidney transplant failure. The transaction involves an upfront payment of $5 million and potential milestone payments totaling $7 million. Vera has also secured a $50 million credit facility with Oxford Finance to support further development. MAU868 is currently in a Phase 2 clinical trial, with results expected in mid-2022. This acquisition aligns with Vera’s strategy to enhance its pipeline for immunological diseases.
Vera Therapeutics announces the appointment of Kimball Hall to its board of directors. Hall, with over 30 years of experience in the pharmaceutical industry, is recognized for her leadership roles at Genentech and Amgen, and her current position as president of Abzena, a contract development and manufacturing organization. Her expertise in drug manufacturing and strategic development is expected to enhance Vera's objectives, particularly in advancing its lead clinical candidate, atacicept, aimed at treating serious immunological diseases.
Vera Therapeutics (Nasdaq: VERA), a biotechnology company focused on immunological diseases, announced that its CEO, Marshall Fordyce, will present at several investor conferences in November 2021. These include the Jefferies London Healthcare Conference (November 16-18) and the Evercore ISI HealthCONx (November 30 - December 2). Fordyce's presentations will discuss Vera’s lead product candidate, atacicept, aimed at treating autoimmune diseases. Replay links for all presentations will be available for 30 days on the company’s website.
Vera Therapeutics reported ongoing progress in its Phase 2a JANUS clinical trial for atacicept, showing substantial and durable reductions in serum Gd-IgA1 levels in patients with IgA nephropathy. Key highlights include a 60% reduction in Gd-IgA1 for the 75mg dose, indicating potential for renal survival benefits. Financially, Vera posted a net loss of $7.6 million for Q3 2021, with $86.2 million in cash as of September 30, 2021. The company is advancing the Phase 2b ORIGIN study and awaits FDA feedback on its lupus nephritis development strategy.